Recent research indicates that taking popular weight loss drugs may help reduce the risk of heart attacks, strokes, and cardiac death.
A study published in the New England Journal of Medicine found that Wegovy, a drug approved by the U.S. Food and Drug Administration for the treatment of obesity, can reduce the risk of cardiac-related issues by up to 44% among overweight or obese individuals without diabetes.
The study was funded by Novo Nordisk, the manufacturer of Wegovy, and involved more than 17,000 participants over the age of 45 with heart disease from 41 countries/regions.
Over an average of 34 months, subjects taking Wegovy not only experienced a lower risk of heart complications but also had reduced blood pressure levels and greater weight loss compared to the placebo group.
Wegovy belongs to a class of drugs known as GLP-1 receptor agonists, which help individuals increase insulin levels in the body, thereby lowering blood sugar levels.
The active ingredient in the drug, semaglutide, aids in weight loss by slowing the movement of food through the stomach and suppressing appetite.
In the study, nearly 17% of Wegovy users reported side effects, including heart, gastrointestinal, and neurological issues severe enough for them to withdraw from the research.
The most common side effects among all weight loss medications were nausea and constipation, but there were also reports of irreversible gallbladder and pancreatic diseases.
The manufacturers of these drugs recommend discussing the side effect profile and personalized risks with healthcare professionals before starting use.
Source: U.S. Chinese Network
Do foreigners have any misconceptions about the Terracotta Army?
U.S. civil servants receiving gifts afterward is not illegal! Considered a tip.
Giving someone roses leaves a lingering fragrance in your hand 
“Share”
